Quote | Tryp Therapeutics Inc Com (OTCMKTS:TRYPF)
Last: | $0.049 |
---|---|
Change Percent: | -5.96% |
Open: | $0.0498 |
Close: | $0.049 |
High: | $0.0498 |
Low: | $0.0467 |
Volume: | 399,838 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Tryp Therapeutics Inc Com (OTCMKTS:TRYPF)
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...
KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 (" Exopharm ") have approved the previously announced plan of arrangement (the " Arrangemen...
Message Board Posts | Tryp Therapeutics Inc Com (OTCMKTS:TRYPF)
Subject | By | Source | When |
---|---|---|---|
New $TRYP CEO interview: https://youtu.be/VZWvVG686bgNext Wav | Investopotia | investorshub | 02/01/2022 3:18:43 PM |
Ran with a profit. LOL. It's been | Bruinfan4ever | investorshub | 01/24/2022 4:42:24 PM |
Don't care because l took my money and | 49andretired | investorshub | 01/24/2022 4:27:53 PM |
This thing is going to a penny. So sad. | Bruinfan4ever | investorshub | 01/24/2022 4:23:00 PM |
Well said :) | MADDSTACKER | investorshub | 01/20/2022 1:51:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...
KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 (" Exopharm ") have approved the previously announced plan of arrangement (the " Arrangemen...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangeme...